Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1933414 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $26.95Day −0.96%Mkt cap $2.2B1Y +98.2%Off 52W high −43.4%Vol (1Y) 106.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 840 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.6% of sh out |
| Days to cover9.8d |
| 13F net flow (QoQ)+9.58% |
| Top-10 13F concentration49.0% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$151.8M |
| ROE−36.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−25.7% |
| 1Y+98.2% |
| 3Y+85.5% |
| Since incept. (ann.)+16.0% |
Total return through 2026-07-28 · series begins 2023-03-15. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)106.6% |
| Ann. volatility (3Y)85.7% |
| Sharpe (1Y)1.06 |
| Sharpe (3Y)0.63 |
| Max drawdown (1Y)−52.5% |
| Max drawdown (3Y)−59.0% |
| Beta (3Y vs SPY)0.70 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Catalys Pacific, LLC | 7.9M | $214M | 9.58% | +0.0% |
| RA CAPITAL MANAGEMENT, L.P. | 7.7M | $208M | 9.32% | +5.0% |
| SAMSARA BIOCAPITAL, LLC | 5.9M | $159M | 7.12% | +0.0% |
| FMR LLC | 4.9M | $132M | 5.89% | −3.9% |
| BlackRock, Inc. | 4.5M | $121M | 5.43% | +3.6% |
| WELLINGTON MANAGEMENT GROUP LLP | 3.4M | $91M | 4.07% | +328.3% |
| STATE STREET CORP | 2.9M | $80M | 3.56% | −7.8% |
| Caligan Partners LP | 2.8M | $75M | 3.36% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 110.1% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 8,531,291 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.47 | — | — | — |
| 2025-09-30 | 2025-11-10 | −$0.52 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.66 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.79 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
